US Food and Drug Administration Approval Summary: Ribociclib With an Aromatase Inhibitor in the Adjuvant Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Stage II and III High-Risk Early Breast Cancer Treatment Setting.

已取消 20 由 yantai yang kong 发布于 2025/8/16 17:16:26

DOI:10.1200/JCO-25-00167
文献类型：期刊论文
补充材料：只需要正文
文献链接：https://doi.org/10.1200/JCO-24-01502
管理员驳回:超时未应助，系统关闭。如求助信息不完整（标题、DOI、原文链接），可以补充后重新发布求助。

其它数据库

Abstract：PURPOSE On September 17, 2024, the US Food and Drug Administration (FDA) approved ribociclib in combination with an aromatase inhibitor (AI) for the adjuvant treatment of adults with hormon

应助信息

2025-08-16

Book学术机器人

2025/8/16 17:16:26 未找到该文献，机器人已退出，请等待人工下载

2025/8/16 17:16:26 Book学术AI机器人收到请求，开始寻找文献

2025/8/16 17:16:26 已向机器人发送请求

2025-08-16

yantai yang kong 发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:Association for Computing Machinery (ACM)A new type design of glass curtain wall cleaning robot